SRI International has acquired Quality Clinical Labs (QCL). QCL is the only commercial laboratory of its type in California performing clinical pathology analyses in compliance with Good Laboratory Practice (GLP) regulations. Founded in 1997, QCL specializes in clinical hematology and chemistry evaluations. The company serves approximately 50 biotechnology and pharmaceutical clients throughout the San Francisco Bay area, including SRI.
"The clinical pathology work performed by QCL is an important addition to the preclinical services that SRI provides its clients," said Jon Mirsalis, Ph.D., managing director of SRI's Biosciences Division. "This was a natural extension of our long relationship with QCL. We are tremendously pleased to integrate QCL into our organization and welcome QCL staff to SRI."
"QCL's partnership with SRI will offer our clients valuable benefits," said Christina Tang, director of QCL. "SRI is a nonprofit institute fully committed to bringing its innovations to the marketplace and to patients. In addition, they have Resources for growth, a comprehensive range of services, and a reputation for quality. Together we will continue to provide clients with a comprehensive set of high-value services." Ms. Tang will continue to lead the QCL team, which will operate under its present name and from its current location in Mountain View, California.
The Biosciences Division of SRI performs basic research on disease mechanisms, drug discovery and the development of biologics, and full-service preclinical contract research and development.